CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 135 filers reported holding CRISPR THERAPEUTICS AG in Q1 2018. The put-call ratio across all filers is 3.59 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,726 | -19.8% | 1,590 | 0.0% | 0.00% | – |
| Q2 2023 | $90,661 | +16596.3% | 1,590 | +13150.0% | 0.00% | – |
| Q1 2023 | $543 | -99.4% | 12 | -99.2% | 0.00% | – |
| Q1 2022 | $98,000 | -35.1% | 1,576 | -21.2% | 0.00% | – |
| Q4 2021 | $151,000 | -65.4% | 2,000 | -48.7% | 0.00% | -100.0% |
| Q3 2021 | $436,000 | +722.6% | 3,900 | +516.1% | 0.00% | – |
| Q3 2020 | $53,000 | -53.1% | 633 | -58.0% | 0.00% | – |
| Q2 2020 | $113,000 | -61.4% | 1,508 | -78.0% | 0.00% | -100.0% |
| Q1 2020 | $293,000 | -86.4% | 6,857 | -93.2% | 0.00% | -75.0% |
| Q4 2017 | $2,147,000 | – | 101,188 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |